Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NCATS grant to spur epigenetic database
August 2014
SHARING OPTIONS:

MALVERN, Pa.—The National Center for Advancing Translational Sciences (NCATS) has awarded Reaction Biology Corporation (RBC) a Phase 1 SBIR grant for the creation of a database of epigenetic drug interactions. With the funding, RBC will undertake a one-year project to assay a library of more than 1,400 compounds—including nearly every U.S. Food and Drug Administration-approved drug—against more than 30 epigenetic modifying enzymes, generating data that could shed light on the mechanism of existing drugs’ side effects, aid in the creation of new compounds against conditions with known epigenetic mediators and perhaps highlight drugs that could be repurposed.
 
“This project will represent the first systematic look at how current pharmaceuticals affect epigenetic function,” said Dr. Haiching Ma, chief science officer of RBC and the study’s principal investigator. “The potential exists for some exciting developments as a result. We’re very pleased that NCATS saw the same potential in this project as we did.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.